Abstract / Description of output
A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting.
Original language | English |
---|---|
Pages (from-to) | 2688-95 |
Number of pages | 8 |
Journal | Clinical Cancer Research |
Volume | 16 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2010 |